Andrew Craig Miller - 01 Nov 2021 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role: Chief Operating Officer
Signature: /s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Nov 2021
Net transactions value: -$324,141
Form type: 4
Filing time: 03 Nov 2021, 16:18:22 UTC
Previous filing: 05 Oct 2021
Next filing: 17 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$77,380	+26,500	+95%	$2.92^*	54,327	02 Nov 2021	Direct
transaction	KRTX	Common Stock	Sale	$13,667	-100	-0.18%	$136.67	54,227	01 Nov 2021	Direct	F1
transaction	KRTX	Common Stock	Sale	$69,935	-500	-0.92%	$139.87	53,727	01 Nov 2021	Direct	F1, F2
transaction	KRTX	Common Stock	Sale	$56,296	-400	-0.74%	$140.74	53,327	01 Nov 2021	Direct	F1, F3
transaction	KRTX	Common Stock	Sale	$111,864	-787	-1.5%	$142.14	52,540	01 Nov 2021	Direct	F1, F4
transaction	KRTX	Common Stock	Sale	$106,397	-740	-1.4%	$143.78	51,800	01 Nov 2021	Direct	F1, F5
transaction	KRTX	Common Stock	Sale	$43,362	-300	-0.58%	$144.54	51,500	01 Nov 2021	Direct	F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-26,500	-31%	$0.000000	58,417	02 Nov 2021	Common Stock	26,500	$2.92	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.48 to $140.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (6) to this Form 4.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.55 to $141.18, inclusive.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.93 to $142.85, inclusive.
F5	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.35 to $144.24, inclusive.
F6	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.46 to $144.67, inclusive.
F7	This option vested as to 1/16th of the shares underlying the option award on the vesting commencement date of July 18, 2016 and as to an additional 1/16th of the shares on each three month anniversary thereafter.